Geron is speculated to be a takeover target, but I believe it shouldn't sell at current prices, especially given its strong market potential. Geron's imetelstat, now Rytelo, has shown impressive ...

FOSTER CITY, Calif., January 21, 2025--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an ...

The last time I wrote about Geron Corporation (NASDAQ:GERN) it was in a Seeking Alpha article entitled “Geron: FDA PDUFA Review With Continued Imetelstat Advancement.” In that article ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2024 ...

In this article, we are going to take a look at where Geron Corporation (NASDAQ:GERN) stands against other stocks under $5 with biggest upside potential. On January 20, Bloomberg reported that ...

Geron Co. has a 12-month low of $1.64 and a 12-month high of $5.34. The company has a market capitalization of $1.77 billion, a P/E ratio of -9.16 and a beta of 0.53.

Fitting baju merupakan proses mencoba dan menyesuaikan pakaian dengan bentuk dan ukuran tubuh seseorang. Istilah ini berasal dari bahasa Inggris "fit" yang berarti cocok atau sesuai. Dalam konteks ...

Geron is also testing the drug for myelofibrosis (MF), another form of bone marrow cancer, and expects data from the phase 3 IMpactMF trial of imetelstat in relapsed/refractory MF in 2024.

But the truth is far more simple: Star Trek: The Original Series is really, really good. Honestly, most of season one and two are good to great (also, there’s a third season!) but these 20 ...

Many people today deny the reality of original sin. Modern thinkers claim that evolution disproves it. Some object to the idea of inheriting sin from our parents, while others simply deny sin itself.

Geron's first-in-class cancer drug Rytelo, recently approved by the FDA for myelodysplastic syndromes (MDS), is priced three to four times higher than it should be, according to the Institute for ...